- Conditions
- Endometrial Cancer
- Interventions
- Lymphoseek, Single Photon Emission Computed Tomography (SPECT), Indocyanine Green (ICG), Neoprobe Gamma Detection System NPB11L(Model1102)
- Drug · Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Iron Deficiency Anemia
- Interventions
- Ferric Carboxymaltose (FCM), Iron Sucrose / Iron Dextran
- Drug
- Lead sponsor
- American Regent, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Norristown, Pennsylvania
- Conditions
- Uterine Cervical Neoplasms
- Interventions
- Tc99m tilmanocept
- Drug
- Lead sponsor
- Cardinal Health 414, LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 4
- States / cities
- La Jolla, California • Miami, Florida • Winston-Salem, North Carolina + 1 more
- Conditions
- Anemia
- Interventions
- Iron Supplement, control
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- Up to 8 Weeks
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Keratitis Bacterial
- Interventions
- Moxifloxacin Ophthalmic, Difluprednate Ophthalmic, Riboflavin Ophthalmic, Topical Placebo
- Drug · Other
- Lead sponsor
- Thomas M. Lietman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- San Francisco, California • Miami, Florida
- Conditions
- Head and Neck Carcinoma, Localized Head and Neck Carcinoma, Metastatic Head and Neck Carcinoma, Recurrent Head and Neck Carcinoma
- Interventions
- Personalized ultrafractionated stereotactic adaptive radiotherapy, Volume Modulated Arc Therapy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Best Practice, University of Washington Quality of Life Scale, Version 4, Functional Assessment of Cancer Therapy-Head & Neck
- Procedure · Radiation · Other + 1 more
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Rheumatoid Arthritis
- Interventions
- Tc 99m tilmanocept
- Drug
- Lead sponsor
- Navidea Biopharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Beverly Hills, California • Chicago, Illinois
- Conditions
- Iron Deficiency Anemia
- Interventions
- Iron Sucrose
- Drug
- Lead sponsor
- American Regent, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Norristown, Pennsylvania
- Conditions
- Respiratory Distress Syndrome, Adult, Head Injuries, Closed, Shock, Shock, Traumatic
- Interventions
- Hypertonic Saline-Dextran Solution, Lactated Ringer's Solution
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Oligometastatic Disease
- Interventions
- IMSA101, Immune checkpoint inhibitor, PULSAR
- Drug · Radiation
- Lead sponsor
- ImmuneSensor Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Irvine, California • Kansas City, Kansas • New Brunswick, New Jersey + 5 more
- Conditions
- Keratoconus
- Interventions
- Riboflavin-5-phosphate, Sham cross-linking
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 16 Years to 35 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Amherst, New York • Buffalo, New York
- Conditions
- Conjunctivitis, Allergic
- Interventions
- Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Iron Deficiency Anemia of Pregnancy, Iron Malabsorption
- Interventions
- Iron dextran, Ferrous sulfate 325mg
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • St Louis, Missouri
- Conditions
- Anemia, Iron Deficiency, Delivery Complication
- Interventions
- Ferrous sulfate, Iron dextran
- Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Breast Cancer
- Interventions
- Tilmanocept, Sulfur Colloid
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Keratoconus
- Interventions
- Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light, Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light
- Drug
- Lead sponsor
- Joseph B. Ciolino, MD
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Kidney Disease, Acute Kidney Injury
- Interventions
- 75 mg / 6 mL VFI™
- Device
- Lead sponsor
- FAST BioMedical
- Industry
- Eligibility
- 19 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Central Nervous System Neoplasms, Central Nervous System Tumor
- Interventions
- Tc-99m tilmanocept
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Iron Deficiency Anemia
- Interventions
- Iron Supplement, multivitamin
- Dietary Supplement
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 24 Weeks to 32 Weeks
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 2 Diabetes, Diabetes Type 2, Diabetic Nephropathies, Nephropathy, Obesity, Adolescent Obesity, Diabetic Kidney Disease
- Interventions
- Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, Dextran 40, Renal Biopsy, Positron Emission Tomography
- Drug · Procedure · Radiation
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Years to 26 Years
- Enrollment
- 57 participants
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors, Hodgkin's Disease, Myelofibrosis
- Interventions
- Total Body Irradiation with Fludarabine in UCB Transplants
- Procedure
- Lead sponsor
- Duke University
- Other
- Eligibility
- 14 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Iron-deficiency
- Interventions
- Iron Sulfate
- Drug
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 7 Days to 4 Weeks
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- Lymphoseek
- Drug
- Lead sponsor
- Navidea Biopharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 13
- States / cities
- Birminham, Alabama • La Jolla, California • San Diego, California + 10 more
- Conditions
- Hyperopia, Hyperopic Astigmatism
- Interventions
- riboflavin ophthalmic solution, 0% dextran, UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA), UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off), Laser-assisted in situ keratomileusis
- Drug · Device · Procedure
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- San Diego, California • Waltham, Massachusetts • Teaneck, New Jersey + 2 more